European Commission Approves CARVYKTI (Cilta-Cel) for Relapsed and Refractory Multiple Myeloma Patients Who Have Received At Least One Prior Line of Therapy (https://www.myeloma.org/news-events/multiple-myeloma-news/EC-approves-carvykti-rrmm)